rucaparib + atezolizumab

Rucaparib + atezolizumab is an investigational combination therapy composed of two distinct medicines: **rucaparib**, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), and **atezolizumab**, a monoclonal antibody that inhibits PD-L1. Rucaparib interferes with the repair of single-stranded DNA breaks via PARP inhibition, leading to synthetic lethality especially in BRCA-mutated and homologous recombination-deficient tumors. Atezolizumab blocks PD-L1, preventing it from binding and inhibiting PD-1 and B7.1 receptors on T cells, thereby enhancing anti-tumor immunity. The combination is being explored for synergistic effects on anti-tumor immunity and DNA damage response, primarily for **advanced gynecologic cancers** (including ovarian and endometrial cancers) and **triple-negative breast cancer**. Clinical trials have shown acceptable safety and preliminary activity, with particular benefit signal in BRCA-mutated tumors and tumors with high pre-treatment levels of PD-L1 and CD8+ T cells[1][2][3][4].

Brand names

RubracaTecentriq

Other names

rucaparib camsylateatezolizumab-gxjs